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A small number of rare, recurrent genomic copy number variants (CNVs) are known to
substantially increase susceptibility to schizophrenia. As a consequence of the low fecundity
in people with schizophrenia and other neurodevelopmental phenotypes to which these CNVs
contribute, CNVs with large effects on risk are likely to be rapidly removed from the population
by natural selection. Accordingly, such CNVs must frequently occur as recurrent de novo
mutations. In a sample of 662 schizophrenia proband–parent trios, we found that rare de novo
CNV mutations were significantly more frequent in cases (5.1% all cases, 5.5% family history
negative) compared with 2.2% among 2623 controls, confirming the involvement of de novo
CNVs in the pathogenesis of schizophrenia. Eight de novo CNVs occurred at four known
schizophrenia loci (3q29, 15q11.2, 15q13.3 and 16p11.2). De novo CNVs of known pathogenic
significance in other genomic disorders were also observed, including deletion at the TAR
(thrombocytopenia absent radius) region on 1q21.1 and duplication at the WBS (Williams–
Beuren syndrome) region at 7q11.23. Multiple de novos spanned genes encoding members of
the DLG (discs large) family of membrane-associated guanylate kinases (MAGUKs) that are
components of the postsynaptic density (PSD). Two de novos also affected EHMT1, a histone
methyl transferase known to directly regulate DLG family members. Using a systems biology
approach and merging novel CNV and proteomics data sets, systematic analysis of synaptic
protein complexes showed that, compared with control CNVs, case de novos were
significantly enriched for the PSD proteome (P=1.72 106). This was largely explained
by enrichment for members of the N-methyl-D-aspartate receptor (NMDAR) (P=4.24 106) and
neuronal activity-regulated cytoskeleton-associated protein (ARC) (P=3.78 108) postsynap-
tic signalling complexes. In an analysis of 18 492 subjects (7907 cases and 10585 controls),
case CNVs were enriched for members of the NMDAR complex (P=0.0015) but not ARC
(P=0.14). Our data indicate that defects in NMDAR postsynaptic signalling and, possibly, ARC
complexes, which are known to be important in synaptic plasticity and cognition, play a
significant role in the pathogenesis of schizophrenia.
Molecular Psychiatry (2012) 17, 142–153; doi:10.1038/mp.2011.154; published online 15 November 2011
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Introduction
Genome-wide association studies have found strong
evidence for association between schizophrenia and a
number of genetic variants, both common and rare.1
So far, the evidence for rare variants comes mainly
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from the analysis of deletions and duplications of
segments of DNA known as copy number variants
(CNVs). Cumulatively, as a general class, large
( > 100 kb) rare ( < 1%) CNVs occur more frequently
in those with schizophrenia2,3 than controls, and
several individual CNV loci have been strongly
implicated as risk factors for schizophrenia with high
degrees of statistical confidence. These include
deletions at 1q21.1, NRXN1, 3q29, 15q11.2, 15q13.3,
22q11.2 and duplications at VIPR2, 16p11.2, 16p13.1
and 15q11-q13.2,4–13 Pleiotropic effects are common,
the same CNV often conferring risk for a range of
neurodevelopmental phenotypes including autism,
mental retardation, attention deficit hyperactivity
disorder and epilepsy, although interestingly, and in
contrast to the findings with common risk alleles,
there is little evidence that schizophrenia-associated
CNVs confer risk for bipolar disorder.14
All of the currently known risk CNVs are rare
(control frequencies typically < 0.001) and confer
substantial effects on risk (odds ratios 3–30). The
known risk CNVs occur in 2–3% of cases, but it is
likely that many other risk CNV loci remain to be
identified. Most schizophrenia-associated CNVs span
multiple genes, limiting our ability to make strong
inferences regarding pathogenesis. Important excep-
tions are deletions of NRXN1, encoding the presy-
naptic neuronal cell adhesion molecule neurexin
1,11,15 pointing to the importance of as yet unspecified
abnormalities of synaptic function in the disorder.
Also, obscuring mechanistic insights from the CNV
data are that most reported CNVs occurring in cases
are too rare to allow clear demonstration of associa-
tion statistically. One way to circumvent this is to test
whether particular functionally related groups or sets
of genes are enriched among case CNVs, rather than
trying to interpret the results from individual CNVs.
A limitation of this approach is that the enrichment of
CNVs seen in case–control studies is modest;2 indeed,
one large study has reported no overall excess of
CNVs in cases at all.4 This implies that among sets of
CNVs drawn from cases, only a small proportion can
be expected to be true risk factors for the disorder.
Nevertheless, gene-set enrichment studies have
supported conclusions drawn from consideration of
genes affected by individual CNVs in schizophrenia16
by observing enrichment in schizophrenia of genes
involved in a range of brain functions, for example,
those encoding products involved in nitric oxide
signalling, synaptic long-term potentiation and gluta-
mate receptor signalling,17 or genes in a broad
category corresponding to the gene ontology (GO)
category ‘synaptic transmission’.18 However, it has
been noted that the early gene-set studies did not
allow for important confounders, in particular
the large size of genes implicated in brain function,
and that the conclusions that can be drawn are
consequently unclear.19
Schizophrenia is associated with reduced fecund-
ity, B40% that of the general population,20 or even
lower according to the largest population-based
study.21 It follows that schizophrenia-related muta-
tions of large effect should be rare because of intense
purifying selection, and those that occur in multiple
unrelated individuals are likely to do so through
independent de novo mutations.7,22–24 One study on
de novo CNV mutation in schizophrenia24 showed
that the rate of de novo CNV mutation in probands
with no family history was 8 times higher in cases
than in controls. This marked elevation in the rate of
de novo CNVs contrasts with the relatively modest
elevation in the rate of CNVs seen in case–control
studies,2,4 and suggests that sets of de novos might be
more informative for gene-set enrichment analyses.
Here, we report the largest analysis of de novo
CNVs in schizophrenia to date. Our aims were to
identify novel CNVs that increase risk of schizophre-
nia and to illuminate aspects of the pathophysiology
of the disorder through gene-set enrichment analyses
informed by recently curated proteomics data sets of
synaptic protein complexes.
Materials and methods
Samples
Bulgaria The sample for de novo CNV analysis
comprised 662 Bulgarian parent–proband trios from
638 families. We did not exclude probands (N=61)
with a history of psychosis in a parent as none of the
risk CNVs identified to date are sufficiently penetrant
to fully explain the disorder in carriers. All cases had
been hospitalised and met DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders-fourth edition)
criteria for schizophrenia or schizoaffective disorder
based upon SCAN (Schedules for Clinical Assessment
in Neuropsychiatry) interview by psychiatrists, and
review of case notes. Cases were recruited from
general adult psychiatric services and were typical
of those attending those services. Although they did
not have formal IQ assessments, all attended
mainstream schools from which people with known
mental retardation were excluded. All participants
provided informed consent. Further details
concerning ascertainment and diagnostic practices
are provided in the Supplementary Material. All
DNA samples were derived from peripheral venous
blood.
Icelandic control de novos deCODE Genetics
provided data for 2623 complete parent–offspring
trios from the Icelandic population.7 Probands known
to be affected with neurodevelopmental/psychiatric
disorders (schizophrenia, autism, attention deficit
hyperactivity disorder, mental retardation and
bipolar affective disorder) had been excluded.
Autism case and control de novos Data on de novo
rates in autism cases and their unaffected siblings are
directly taken from the recent large study of Sanders
et al.25 based upon the Illumina (San Diego, CA, USA)
1M high-density array.
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Case–control data sets We used four large publicly
available data sets to which we also had access to the
raw data. (1) The International Schizophrenia
Consortium (ISC),2 which included 3391 cases and
3181 controls genotyped with Affymetrix 6.0 or 5.0
arrays (Affymetrix, Santa Clara, CA, USA). Note that
328 Bulgarian cases from that study are probands in
our trios (although their parents were not genotyped
for de novo calling in the ISC study). We excluded
those subjects from the ISC data. The ISC also included
605 unrelated controls recruited by us in Bulgaria
(details in ref. 2) and those publicly available data were
included in the present study. (2) The Molecular
Genetics of Schizophrenia (MGS) Consortium,4 which
included 3192 cases and 3437 controls genotyped with
Affymetrix 6.0 arrays. (3) A UK case–control study of
471 schizophrenia and 2792 controls genotyped using
the Affymetrix (Affymetrix) GeneChip500K Mapping
Array (see ref. 3 for details of the sample and CNV
calling). (4) CNV data reported by Ikeda et al.26
comprising a Japanese sample of 519 cases and 513
controls. Including the data from the current study on
transmissions and non-transmissions to affected off-
spring, and excluding the 328 overlapping Bulgarian
cases, the combined case–control data sets contain a
total of 7907 independent cases and 10585 controls.
Genotyping and CNV analysis
Bulgarian samples Full details are provided in
the Supplementary Material (Sections 1–3). All
participants were genotyped with Affymetrix 6.0
arrays (Affymetrix) at the Broad Institute of Harvard
and Massachusetts Institute of Technology. As an
initial screen, we used Genotyping Console 4.0
software (Affymetrix, Santa Clara, CA, USA) to call
autosomal CNVs, restricting initial calls to X10 kb
and X10 probes. We next excluded individuals
with >50 CNV calls, as these were outliers from
the distribution, followed by CNV loci with a frequ-
ency >1% in the whole sample. We then excluded
putative CNVs <15 kb, covered by <15 probes, or
where > 50% of their length overlapped low copy
repeats. Calls compatible with a de novo were made if
a proband CNV was not spanned >50% of its length
by a CNV in either parent. Probands who had large
numbers of apparent de novos ( > 10) were excluded.
After this initial screen with relaxed criteria to
capture as many potential de novos as possible, we
measured probe Log2 ratios derived from PennCNV.27
We then used a slight modification of the MeZOD
algorithm12 (Supplementary Section 3) to visualise
outlier signals in probands potentially indicative of
de novos (Figure 1). Again, we used relaxed criteria,
only excluding clear false positives (Supplementary
Section 3). For those whose patterns were either
highly suggestive of a de novo (N=40, Figure 1a) or
were ambiguous (N=33, Figure 1b), proband and
parent DNAs were examined on custom Agilent
SurePrint G3 Human CGH Microarrays on which
50–200 probes were placed to cover each CNV
(depending on CNV size). For quality control
purposes, we also included probes on all putative
de novos identified by the first-pass Genotyping
Console analysis, but that were subsequently
rejected as false positives by the MeZOD method.
To re-call CNVs in the Bulgarian controls, we used
the same filtering criteria and accepted only those
considered highly suggestive by the MeZOD.
Although we did not validate these on Agilent arrays,
our calls have a demonstrable low false positive rate
( < 1%, Supplementary Section 4). This is much
less than the corresponding false positive rate for
de novos whose rarity confers more unfavourable
signal-to-noise characteristics.
Icelandic samples These were genotyped using
Illumina bead arrays (HumanHap317, HumanHap370
and HumanHap1M). BeadStudio (Illumina, San Diego,
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Figure 1 Histograms of distributions of z-scores. (a) A
suggestive de novo and (b) an ambiguous de novo MeZOD
call. Black arrows indicate the position of a parent, and red
arrows of a child. The x axis shows the median z-scores for all
individuals for a particular copy number variant (CNV) region.
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CA, USA; version 2.0) was used to call genotypes,
normalise signal intensity data and establish the log R
ratio and B allele frequency at every single-nucleotide
polymorphism. Samples passing quality control were
examined using PennCNV (10.1101/gr.6861907). Calls
required 10 consecutive markers based upon the subset
of markers present on all genotyping chips listed above
(the HumanHap317 content). All putative de novo
events were visually inspected using DosageMiner
software (developed by deCODE Genetics). CNVs
were excluded according to low copy repeat content
and frequency as for the Bulgarian sample. This
resulted in 59 CNVs, an autosomal de novo rate of
2.2%. Given the difference in the platforms, we
undertook a number of analyses to confirm that the
Icelandic de novos are a suitable comparator group for
the case de novos (see Results and Supplementary
Material).
MGS/ISC/UK/Japan. MGS samples were analysed in
the same way as the Bulgarian samples including
MeZOD. Data for ISC2 UK3 and Japanese samples26
were taken from the original publications, and
CNVs at loci of interest were manually verified in
the available raw data (further information in
Supplementary Material).
Gene set analyses
Sets. We collated experimentally defined proteomic
data sets corresponding to the structures listed in Table
2. The details of how those gene sets were collated are
provided in Supplementary Section 10. We also
examined sets based upon the Gene Ontology system
(GO sets) in the gene2go file available from the NCBI
(National Center for Biotechnology Information) on 28
July 2010 (Supplementary Section 11).
Statistical approaches. A gene was considered
‘hit’ if a CNV was overlapped according to the NCBI
Build 36.3. Full details of mapping are given as
Supplementary Section 10.
The impact of biases relating to gene-set analyses of
CNVs have been discussed elsewhere.19 To overcome
those biases, we fitted the following logistic regres-
sion models to the combined set of case and control
(or control de novo) CNVs and compared the change
in deviance between (1) and (2).
(1) logit (pr(case)) =CNV size þ Total number of
genes hit outside the gene set þ number of genes
hit in the gene set.
(2) logit (pr(case)) =CNV size þ Total number of
genes hit outside the gene set.
Significance was assessed by one-sided test of an
excess of genes hit in the gene set by case CNVs. The
inclusion of CNV size allows for case de novo CNVs
being larger than typical CNVs (and thus likely to hit
more genes). Inclusion of the total number of genes hit
outside the gene set in the regression corrects for case
CNVs hitting more genes overall (regardless of
function) than control CNVs. Although explicitly
adjusted for in the above analysis, to confirm that
the results are not due to the fact that de novo CNVs
are more likely to hit genes, we also performed an
analysis restricted to CNVs that hit genes.
We used the same method to compare the number
of genes in gene sets hit by case de novos with those
hit by (1) 1367 CNVs from the 605 Bulgarian
unaffected controls (2) 59 de novos found in Icelandic
controls and (3) 14 control de novos from the
unaffected sibs of autism probands.25 The analyses
control for different sources of potential bias includ-
ing array type (the Bulgarian controls) and the
possibility that de novos have fundamentally differ-
ent characteristics (other than size that is adjusted for)
than control CNVs.
To investigate the impact of using ‘control’ CNVs,
we undertook a random placement analysis compar-
ing the number of de novo CNVs hitting each gene set
with that found when CNV locations were rando-
mised, importantly ensuring that each random assign-
ment hits at least one gene, and that the probability
of a gene being hit was proportional to its length
(Supplementary Section 12).
Partitioning the signals in gene sets. Gene sets are not
fully independent, for example, some members of the
synaptic vesicle set (Table 2) are also members of the
postsynaptic density (PSD). To determine which among
overlapping sets appeared to be responsible for a gene-
set enrichment, we undertook conditional regression
analyses as described in Supplementary Section 13.
Meta-analysis of case–controls. For meta-analysis
combining cases and controls from multiple studies,
we included in the above regression models a ‘‘study’’
term added as an N-level factor (where N=number
of case/control sets being combined). This makes the
analysis robust to differences between studies in chip,
analytic method and other study-specific factors.
Results
We identified 34 confirmed de novo CNVs (Table 1), a
rate in all cases of 5.1%. Detailed descriptions of
individual de novo CNVs are given in Supplementary
Section 6 and in the Discussion section. As in an
earlier study,24 the de novo rate in those with a history
of psychosis in a parent was lower (1.6%) than in
those without such history (5.5%), although this was
not statistically significant. Parents of probands with
de novos were not older at the time of birth of their
children than parents of probands without de novos:
(27.8 vs 28.7 years, respectively, for fathers and 25.1
vs 25.1 years for mothers). Probands with de novo
CNVs (Table 1) did not differ from the rest of the
probands regarding age at onset (23.9 vs 23.8 years,
P=0.9) and average school results (4.5 vs 4.7, P=0.5),
and both sets of probands had similar numbers of
children (0.52 vs 0.59, P=0.6). In those instances (21)
where it was possible to determine the parental
origin, more de novos occurred in the paternal
(P=14) than the maternal (n=7) genome but this
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Table 1 List of de novo CNVs found in the study
Cytoband Location Type Size (bp) Genes Origin of
mutation,
F:M SNPs
Diagnosis Schooling Children Age at
onset/ age
at sampling
Somatic
1q21.1 chr1:144101459–144503409 Del 401 950 16 genes, TAR region 10F:0M SA V good, college 2 40/49 Psoriasis
1q43 chr1:235475280–235639644 Del 164 364 RYR2 12F:0M SZ, par Good — 21/33 Patent ductus arteriosusb
2q21.2 chr2:133504420–133879778 Del 375 358 NAP5 7F:0M SZ, par V good 1 18/25 —
3q13.12 chr3:109330592–110198715 Dupl 868 123 9 genes 11F:0M SZ, cat Pass 2 33/48 —
3q29a chr3:197185548–198825231 Del 1 639 683 21 genes, 3q29 syndrome 56F:0M SZ, par Good, college — 19/45 Congenital heart disease
4q13.3 chr4:70935504–70969553 Del 34 049 HTN1, HTN3 — SZ, cat Excellent, college — 24/33 —
4q21.21 chr4:79944612–80081979 Del 137 367 BMP2K, PAQR3 — SZ, par Excellent 1 32/33 —
6q12 chr6:68675955–68761101 Dupl 85 146 — — SZ, par Excellent — 23/29 Hypertension
7p14.1 chr7:38260614–38307187 Del 46 573 TARP — SA Excellent, university — 17/24 Asthma
7q11.23 chr7:72390286–76445231 Dupl 4 054945 38 genes, WBS region 1F: 45M SZ, dis V good — 17/28 —
7q32.1 chr7:127275795–127447967 Del 172 172 C7orf54, SND1 — SA V good — 25/35 —
8p23.2 chr8:4121968–4299810 Del 177 842 CSMD1 0F:23M SZ, par Excellent, university — 17/37 —
8p23.1 chr8:10066862–10155414 Del 88 552 MSRA — SZ, par Pass — 15/41 —
9p22.3 chr9:16310745–16327782 Del 17 037 — — SA Excellent, university 1 34/37 —
9q31.3 chr9:110859131–111433199 Dupl 574 068 4 genes — SZ, ns Pass — 9/26 —
9q34.3 chr9:139762152–139797423 Dupl 35 271 EHMT1 — SZ, ns V good 2 20/37 Overweight
9q34.3 chr9:139769564–139792102 Del 22 538 EHMT1 — SZ, dis Pass 1 24/36 Overweight
11q14.1 chr11:83472750–83842973 Del 370 223 DLG2 0F:M12 SZ, cat V good, college — 18/22 —
11q14.1 chr11:84006106–84226064 Del 219 958 DLG2 10F:0M SZ, par Pass 2 20/35 —
12q24.13 chr12:111723795–111776045 Del 52 250 RPH3A — SZ, par Good — 21/33 Patent ductus arteriosusb
12q24.33 chr12:130388037–130659530 Dupl 271 493 — — SZ, par Good — 27/33 —
13q14.11 chr13:40319620–41182276 Del 862 656 8 genes 15F:0M SZ, par Good — 22/33 —
14q13.2 chr14:34464771–34627720 Del 162 949 3 genes 1F:0M SA, FHþ Excellent — 16/24 —
15q11.2a chr15:19548923–20852202 Del 1 303 279 8 genes 0F:16M SZ, par Pass — 32/42 —
15q11.2a chr15:20224751–20777909 Dupl 553 158 5 genes 0F:10M SA Pass 1 20/28 —
15q11.2a chr15:20224751–20852202 Dupl 627 451 5 genes 0F:8M SA Good — 29/31 —
15q11.2a chr15:20302446–21038975 Del 736 529 6 genes 19F:0M SZ, par V good 1 17/28 —
15q13.1 chr15:26785056–28289366 Dupl 1 504310 4 genes 0F:2M SZ, dis Pass — 23/43 —
15q13.3a chr15:28707904–30326817 Del 1 591 596 7 genes 93F:0M SZ, par Pass — 31/38 —
15q13.3a chr15:28707904–30299500 Del 1 618 913 7 genes 25F:0M SZ, par V good — 32/52 —
16p11.2a chr16:29488112–30099396 Dupl 611 284 31 genes 21F:0M SZ, par Excellent, college 1 35/46 Rheumatoid arthritis
18p11.31 chr18:3515935–4332609 Del 816 674 DLGAP1, FLJ35776 61F:0M SZ, par Good 1 18/25 —
20p12.1 chr20:14694326–14863051 Del 168 725 MACROD2 2F:0M SZ, cat V good 1 32/37 —
21q21.1 chr21:22698250–22778244 Del 79 994 — — SA Excellent, university — 29/30 Single febrile convulsion
Abbreviations: CNV, copy number variant; SA, schizoaffective disorder; SNP, single-nucleotide polymorphism; SZ, cat, catatonic schizophrenia; SZ, dis, disorganised
schizophrenia; SZ, ns = schizophrenia, not otherwise specified; SZ, par, paranoid schizophrenia; TAR thrombocytopenia absent radius; WBS, Williams–Beuren
syndrome.
aIndicates a known schizophrenia locus.
bSame patient who has two de novos.
Origin of mutation indicates whether the mutation had occurred on the paternal or maternal chromosome. The number of informative SNPs supporting parental origin
are given in the order father(F):mother(M). Additional detail is given in Supplementary Section 6. Coordinates in the paper refer to the UCSC (University of California,
Santa Cruz) human genome assembly hg18 (National Center for Biotechnology Information (NCBI) build 36). Final school results in Bulgaria are reported as 2 = fail,
3 =pass, 4 = good, 5 =very good, 6 = excellent.
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was not statistically significant (P=0.13). The non-
significant excess of paternal de novos was largely
attributable to CNVs that were not generated by
nonallelic homologous recombination, eight such
events being observed on chromosomes of paternal
origin compared with two on those that were
maternally derived, although this is not significantly
different from chance (P=0.06).
In order to estimate the de novo CNV rate in
controls for comparison with cases, we compared the
case de novo rate with that in controls from two
sources, the Icelandic population controls and the
unaffected sibs from a recent large study of autism25
(Supplementary Table S3). The de novo mutation rate
in our cases was higher than in both sets of controls
(2.2%, P=0.00015 and 1.6%, P=0.00008, respec-
tively), both of which had a similar rate (P=0.28)
despite differences in the density of markers in the
control genotyping platforms.
In order to exclude the possibility that the incre-
ased de novo rate seen in cases reflected the different
platforms28 used in our cases and the control studies,
we undertook sensitivity analyses. If the elevation in
de novos in cases is an artefact of greater call
sensitivity in the present study, the enrichment we
observed should be biased towards smaller CNVs,
larger CNVs being called reliably after exclusion of
CNVs spanning complex repeat regions (as we have
done).28 However, relative enrichment for de novos
among cases was similar for large de novos >500kb
(2.1% vs 0.8%, P=0.0014) as it was for small
de novos <200kb (2.3% vs 0.9%, P=0.0035), and
the overall size distribution of case de novos was not
shifted towards smaller CNVs (Figure 2 and Supple-
mentary Table S3) compared with the control
de novos. In general, duplications are less easily
detected by microarrays than deletions. To exclude
the possibility that the excess of de novos in cases
reflects a lower sensitivity of the control platforms to
detect duplications, we also examined the duplica-
tion/deletion ratios in the data sets. These were not
significantly different (P>0.35 for each sample),
although contrary to the hypothesis of a selective
loss of sensitivity to detect duplications, both sets of
controls actually had a higher proportion of duplica-
tions (Icelandic = 0.39, Autism controls = 0.36) than
the cases (0.29). Further details on the size distribu-
tion of the de novo CNV are given in Supplementary
Section 8, and of the full sensitivity analyses in
Supplementary Section 1. Finally, we note that the
control rates were similar to those in our experimental
group with an affected parent (who according to an
earlier work24 do not have elevated rates of de novo
mutation), suggesting that technical variation
between our own and other studies does not make a
major impact on our conclusions.
Analysis of de novo loci in case–control studies
We examined the fully independent case–control data
sets for rare CNVs at the novel loci affected by case
de novos, including CNVs only of the same class that
had been observed to have occurred as de novos (that
is, deletions, duplications or both where relevant)
(Supplementary Section 7) that intersected at least
one exon of a gene (details in Supplementary
Table S1). Even after an extremely conservative
approach of excluding all CNVs (deletions and
duplications) at known schizophrenia loci repre-
sented among our de novos (3q29, 15q11.2, 15q13.3
and 16p11.2), we found rates of 0.4% (32/7907) in
cases and 0.21% (22/10 585) in controls, a twofold
enrichment (Fisher one-tailed P=0.012). We did not
obtain evidence for association to individual CNV
loci at a level that would survive correction for
multiple testing (N=19 excluding the known schizo-
phrenia loci, giving a Bonferroni corrected threshold
of P=0.0025). However, nominally significant asso-
ciations (P uncorrected <0.05) were observed for
deletions at DLG2 (P=0.02) and MSRA (P=0.03),
whereas the EHMT1 locus just failed to reach this
uncorrected threshold (P=0.055). Of interest,
although not even nominally significant, we also
observed an excess of CNVs in cases at two other loci
known to be implicated in nonpsychiatric genomic
disorders: deletions of the TAR (thrombocytopenia
absent radius) region (P=0.11) and duplications
of the WBS (Williams–Beuren syndrome) region
(P=0.11).
Gene-set analyses
We initially undertook gene-set analyses based
upon proteomics-based annotations (Table 2 and
Supplementary Section 11). To avoid multiple testing
involved in subgroup analysis, we present the find-
ings for the full sample of de novos, although we note
that exclusion of the single de novo in a proband with
a family history of psychosis in a parent made
essentially no difference to the results. Compared
with Bulgarian control CNVs, we found a highly
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significant excess of PSD genes within case de novos
(P=1.72 106; Table 2). As expected, the results
where the analysis was restricted to CNVs hitting
genes were similar to those of the primary analysis
(data not shown).
Significant enrichments were also observed in
presynaptic vesicle and nuclear gene sets, but not
after conditioning on the PSD (Pmin=0.66), whereas
the PSD gene set remained significantly enriched for
hits after conditioning on the other sets individually
(Pmax=5.20 10
3) or combined (P=0.016) (Supple-
mentary Section 13). The most parsimonious inter-
pretation is that our findings specifically implicate
the PSD, although we cannot exclude the possibility
of effects across multiple functional sets.
To explore our findings in the context of a less
restricted set of classifications, we performed enrich-
ment analyses using the GO annotation. Of all
categories, ‘the synapse’ (GO: 45202) was by two
orders of magnitude the most significantly enriched
(P=9.6109) (Supplementary Section 11 and
Supplementary Table S4) but most of this signal was
attributable to the PSD gene set (P=0.049 after
removing PSD genes, Supplementary Table S5).
Only one subcategory of ‘the synapse’ GO: 45202
was enriched after PSD genes were removed:
GO: 30672 ‘synaptic vesicle membrane’ (P=0.036,
Supplementary Table S5).
Aiming to localise more specifically the source of
the PSD gene-set enrichment, we tested gene sets
encoding PSD components (Table 2 and Figure 3).
Activity-regulated cytoskeleton-associated protein
(ARC; P=3.78108), N-methyl-D-aspartate receptor
(NMDAR; P=4.24 106) and PSD-95 complex
(P=1.17 105) genes were highly significantly
enriched among the de novos. However, conditional
analyses revealed that the relatively small ARC and
NMDAR sets explained both the PSD (conditional
PPSD=0.231) and PSD-95 (conditional PPSD-95=0.603)
enrichments but that the enrichments in ARC and
NMDAR were partially independent of each other
(conditional P=2.17 104 and P=0.019, respec-
tively) (Supplementary Section 13). ARC and
NMDAR sets also explained most of the enrichment
for de novos in ‘the synapse’, this GO category being
only marginally enriched (P=0.017) after those genes
were removed (Supplementary Section 11 and
Supplementary Table S5). After removal of members
of ARC and NMDAR sets, none of the subcategories
comprising the synapse was significantly enriched
Table 2 Enrichment of gene sets for de novo CNV hits in comparison with control CNVs
Gene set N genes N genes hit by CNVs P-value Genes hit by SCZ de novos
SCZ
de novo
(34)
Bulgarian
control
(1367)
Icelandic
control
de novo (59)
Autism
control de
novo (14)
PSD 664 19 49 (1.72 106) 13 (0.045) 4 (0.11) DLG1, DLG2, DLGAP1, RYR2, SND1, STX1A,
MDH2, HSPB1, YWHAG, RPH3A, CYFIP1,
TJP1, ALDOA, TAOK2, MAPK3
ARC complex 25 8 7 (3.78 108) 1 (2.51 104) 0 (0.0049) DLG1, DLG2, DLGAP1, CYFIP1
NMDAR complex 59 8 6 (4.24 106) 2 (0.0061) 0 (0.01) DLG1, DLG2, DLGAP1, STX1A, YWHAG,
TJP1, MAPK3
PSD-95 complex 58 4 3 (1.17 105) 1 (0.017) 0 (0.033) DLG1, DLG2, DLGAP1
mGluR5 complex 37 3 4 (0.026) 2 (0.45) 0 (0.15) YWHAG, RPH3A, ALDOA
Presynapse 426 8 25 (0.033) 8 (0.32) 2 (0.28) STX1A, RPH3A, CYFIP1, ALDOA, MDH2
Synaptic vesicle 333 7 20 (0.014) 8 (0.39) 2 (0.31) STX1A, RPH3A, CYFIP1, ALDOA
Active zone 176 2 6 (0.29) 3 (0.91) 0 (0.26) ALDOA, MDH2
Nucleus 160 5 10 (0.0024) 2 (0.026) 0 (0.018) CYFIP1, TJP1
Mitochondrion 189 3 9 (0.41) 1 (0.11) 0 (0.093) MDH2, BDH1, KIAA0564
Cytoplasm 263 4 11 (0.68) 3 (0.55) 0 (0.15) EIF4H, YWHAG, MSRA, MVP
Endoplasmic reticulum 94 1 3 (0.75) 0 (0.18) 0 (0.31) POR
Endoplasmic reticulum/
Golgi-derived vesicles
94 0 0 0 0
Recycling endosomes 65 0 2 (0.83) 0 0
Early endosomes 17 0 1 (0.82) 0 0
Golgi 31 0 1 (0.82) 0 0
Plasma membrane 50 0 2 (0.61) 0 0
Abbreviations: ARC, activity-regulated cytoskeleton-associated protein; CNV, copy number variant; NMDAR, N-methyl-D-
aspartate receptor; PSD, postsynaptic density; SCZ, schizophrenia.
Gene sets were tested for enrichment in 34 schizophrenia (‘SCZ’) de novo CNVs compared with 1367 CNVs found in 605
Bulgarian controls (‘controls’), 59 de novo CNVs found in 2623 unaffected individuals from the Icelandic population
(‘Icelandic control de novo’) and 14 de novo CNVs found in unaffected siblings of autism proband from the study by Sanders
et al.25 (‘Autism control de novo’). ‘N genes’ refers to number of genes in the set. P-values are presented underneath the
number of genes hit and correspond to one-tailed tests of an excess of gene hits in case CNVs. P-values in bold are significant.
‘N genes hit by CNVs’ refers to the number of times any gene in the set is hit by a CNV. The unique genes hit in each set are
given in the final column. Genes in bold are present in multiple subcellular components.
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except for ‘synaptic vesicle membrane’
(P=4.22 104). These findings suggest enrichments
in the PSD, and the great majority of that in the
synapse GO gene set, is because of the enrichments in
ARC and NMDAR, but that there is residual enrich-
ment elsewhere in the synapse that is captured by
‘synaptic vesicle membrane’ genes (GO: 30672).
To exclude unknown possible sources of confound-
ing arising from the use of control CNVs, we also
compared gene sets hit by de novo CNVs from cases
with those hit in random assignments of gene-hitting
CNVs of the same size, ensuring the probability of a
gene being hit was proportional to its size. Again,
we observed significant enrichment of PSD genes
(P=0.0024), and a highly significant enrichment of
the ARC (2.21108) and NMDAR (2.95104)
complexes (Supplementary Section 12).
To exclude the possibility that our results reflect
general properties of de novo CNVs, we compared
case de novo CNVs with de novo CNVs identified in
the control individuals from Iceland and from the
Autism study by Sanders et al.25 Despite fewer control
CNVs in these samples (N=59 and N=14), and
therefore reduced power, the findings were consistent
with our primary analysis in showing significant
enrichment of ARC and NMDAR (Table 2) as were
those of sensitivity analysis restricted to very large
CNVs ( > 500kb) (ARC P=1.27 104; NMDAR
P=1.72 102).
Finally, we examined the ARC/NMDAR gene sets in
the large case–control data sets. In this completely
independent analysis, case CNVs were significantly
enriched for members of the NMDAR (P=0.0015) but
not ARC complexes (P=0.14). We note that in the
de novo analysis, much of the additional signal for the
ARC complex (over and above that of the NMDAR)
comes from CNVs at 15q11.2 that span CYFIP1.
Although there is strong published evidence for
deletions at this locus being relevant to schizophre-
nia,3,7 this locus was not significantly enriched in the
MGS study,4 and was excluded by the filtering criteria
adopted by the ISC,2 the two studies that combined
comprise a large proportion of the case–control data
set we use in this study.
Discussion
Aiming to identify novel candidate CNV loci for
schizophrenia, and to illuminate aspects of the
pathophysiology of the disorder through gene-set
enrichment analyses, we have conducted the largest
analysis of de novo CNVs in schizophrenia to date.
Although not every observed case de novo CNV is
likely to be pathogenic, the hypothesis that a
substantial proportion of them are likely to be so is
supported by several observations. First, eight of the
de novos occurred at already known schizophrenia
CNV loci (Table 1, marked with footnote ‘a’). Second,
even after conservatively excluding those known loci,
CNVs at the loci affected by case de novos occurred
twice as frequently in cases in a meta-analysis of
the largest available case–control CNV data sets. This
elevation is much higher than the overall increase in
CNV burden in cases in the large published studies.2,4
Third, in the trios sample, the rate of de novo CNVs
Figure 3 Disruption of postsynaptic signalling within
activity-regulated cytoskeleton-associated protein (ARC)
and N-methyl-D-aspartate receptor (NMDAR) complexes by
copy number variants (CNVs). ARC and NMDAR bind to
diverse structural and signalling molecules forming multi-
protein complexes. Functional pathways encoded by these
complexes are disrupted by de novo CNVs at multiple
levels, as indicated by the purple asterisks (number of
asterisks =number of de novos overlapping a gene or gene
family). Calcium influx via the NMDAR, modulated
by calcium release from internal stores (RYR2), drives
downstream pathways whose association with the receptor
is mediated by scaffold proteins (DLG1, DLG2, DLGAP1).
Multiple pathways converge on ERK kinases (extracellular
signal-regulated kinases), a focal point in the regulation of
ARC transcription, dendritic localisation and local transla-
tion.47 ARC mRNA is transported to sites of synaptic activity
in complexes containing CYFIP1, dissociation of which is
required for ARC translation.49 CYFIP1 also regulates
translation of CAMKII,49 a key component of NMDAR
complexes. Although not identified in this study, deletions
of synaptic adhesion protein NRXN1 (blue asterisk) have
previously been found in schizophrenia.29 CNVs disrupting
genes within these same functional pathways have also
been identified in autism30 (black asterisks).
Involvement of de novo CNVs in the pathogenesis of schizophrenia
G Kirov et al
149
Molecular Psychiatry
was more than twice that observed in other control
samples (Supplementary Table S3), suggesting that at
least 50% of the case de novos are relevant to the
pathophysiology of schizophrenia.
Our estimate of the de novo rate is lower than initial
reports in autism23 and schizophrenia24 but is com-
parable with more recent estimates in autism.25,29,30
Post hoc evaluation suggests it is unlikely that our
filtering steps excluded large numbers of true de novo
CNVs within our target size range. Of the 34 Agilent-
validated de novos, 91% (N=31) had been rated
(using MeZOD) as highly suggestive, whereas only
9% (N=3) had been called as ambiguous. Conversely,
none of 33 putative de novos called by the Genotyping
Console that were rejected by MeZOD were confirmed
by Agilent.
It is notable that two previously documented
schizophrenia loci, at 15q11.2 and 15q13.3, were
each found more than once as de novos (Table 1). Two
other loci were represented by two de novo CNVs
each: EHMT1 (encoding Eu-HMTase1), a histone H3
Lys 9 (H3-K9) methyltransferase, and DLG2 (encoding
discs, large homologue 2). Moreover, one de novo
spanned each of the related genes DLG1 (whose
orthologue in Drosophila is also dlg1) and DLGAP1
(encoding discs large associated protein 1).
At EHMT1 we observed a total of two de novos,
three additional exonic CNVs in cases and one in a
control. EHMT1 haploinsufficieny has been impli-
cated as the cause of the 9q subtelomeric deletion
syndrome (9qSTDS) characterised by moderate-to-
severe mental retardation, childhood hypotonia and
facial dysmorphisms, as well as a high prevalence of
psychiatric symptoms in adulthood.31 A recent study
has also reported strong evidence that deletions at
EHMT1 are highly penetrant for phenotypes compris-
ing developmental delay and a range of congenital
anomalies.32 With this additional evidence for the
involvement of this gene in neurodevelopmental
phenotypes, our data point to EHMT1 as a schizo-
phrenia susceptibility gene. Intriguingly, in Droso-
phila, ehmt coordinates epigenetic changes important
in regulating cognition.33 Our findings at this locus
thus suggest a role for epigenetic mechanisms in at
least some cases of schizophrenia, and potentially
point the way to novel therapeutic opportunities
as the developmental effects of ehmt mutation on
cognition are reversible.31
The DLG (discs large) family of membrane-asso-
ciated guanylate kinases (MAGUKs), which were hit
by multiple case de novo CNVs, are components of
postsynaptic signalling complexes that are embedded
within the larger group of over 1000 proteins that
make up the PSD.34 They are associated with NMDA
receptors and are highly concentrated in synapses.
Remarkably, the orthologue of DLG2 in Drosophila
(dlg1) is directly regulated by the orthologue of
EHMT1 (emht also known as G9a).33 CNVs spanning
DLG1 and DLG2 have been reported before in
schizophrenia4,6,17 whereas other members of the
family (DLG3 and DLGAP2) have been implicated in
mental retardation35 and autism.30,36 Together with
our observation of multiple de novos spanning
members of this family, and the nominally significant
association of exonic CNVs at DLG2 in the case–
control analysis, the findings strongly suggest that the
CNVs we report in DLG-related genes are likely to be
of pathogenic relevance to schizophrenia.
Although not strongly implicated by our study, a
number of singleton de novo CNVs are also of note as
they are at loci known to be associated with rare
genomic disorders. The first is a deletion at 1q21.1
reported in TAR syndrome37 (which does not overlap
the known 1q21.1 schizophrenia locus2,7). We found
the TAR region deleted in three more cases and only
one control from the extended case–control samples.
Again, deletions at this locus have very recently been
strongly implicated in developmental delay.32
Another region is a duplication at the locus causing
the 7q11.23 microduplication syndrome (which is
deleted in Williams–Beuren Syndrome), the promi-
nent features of which include autism and develop-
mental delay.38 Duplications at the WBS region were
found in three more cases and one control. Although
this excess is not statistically significant (P=0.11,
uncorrected), given duplications at this locus have
also recently been identified increasing susceptibility
for autism25 and developmental delay,32 it seems
likely that the observations in the present study point
to the involvement of this locus in schizophrenia as
well. Further details about each of these loci are
provided in Supplementary Section 6.
Given that our data suggest de novo CNVs are
highly enriched for pathogenic loci, we sought
evidence for convergence of de novo events onto
specific biological pathways using a hypothesis-led,
systems biology approach. Many of the CNVs robustly
implicated in schizophrenia are also implicated in
neurodevelopmental disorders in which cognitive
impairment is common.39–41 Moreover, as discussed
in the Introduction, it has been hypothesised that
schizophrenia CNVs are enriched for genes encoding
proteins associated with synaptic function. Our
findings of apparent convergence of de novo CNVs
onto genes encoding MAGUK proteins broadly sup-
port this synaptic hypothesis and suggested that more
refined examination of synaptic genes is warranted.
Cognitive deficits are increasingly recognised as
core features of schizophrenia, and it has long been
known that antagonism of NMDA receptors at
glutamatergic synapses can induce a schizophrenia-
like psychosis that includes some of those deficits.42
This has led to a glutamate hypofunction hypothesis
of schizophrenia. Glutamate receptors form multi-
protein complexes with large sets of scaffold and
signalling proteins including MAGUKs43 that are
embedded in the PSD. It is clear that disruption of a
number of synaptic proteins linked to glutamate
receptor signalling alters cognitive function in
rodents.44 The composition of the PSD has recently
been identified in humans by some of the present
authors,34 affording us an unprecedented opportunity
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to investigate the role of this complex in schizo-
phrenia. Specifically, we tested the hypothesis that
de novo CNVs in cases are enriched for genes encoding
members of this complex.
We first compared the case de novos with a set of
control CNVs drawn from the same population as the
trios. Although those CNVs must have originally
occurred as de novo mutations, predominantly trans-
mitted CNVs clearly have different characteristics
from the case de novos, most obviously size. Although
our set-based analyses allow for size differences, to
ensure our findings were robust to the control data
set, we also compared gene sets hit by case de novo
CNVs with those hit in random assignments of gene-
hitting CNVs of the same size and obtained very
similar gene-set enrichments. Finally, in order to
exclude the possibility that our findings reflected
general properties of de novo CNVs, we compared
case de novo CNVs to two sets of control de novos,
one drawn from the Icelandic population and the
other from a much smaller sample of unaffected sibs
of people with autism. Despite the wide disparities in
the sources of the control CNVs, and the potential
for different sources of bias, the results converge in
pointing to the involvement of the synapse, the PSD,
and more specifically, ARC and NMDAR complexes.
Finally, and fully independent of those analyses, we
show a significant enrichment for genes in the
NMDAR complex in a meta-analysis of case–control
data sets. We think it likely that the weaker finding for
the NMDAR complex in the large case–control study
compared with the relatively small de novo study,
and the absence of association to ARC in the former,
reflects the much lower power of the case–control
design as a result of poorer enrichment for pathogenic
CNVs.
This study adds to an accumulating body of
evidence from human and animal genetic studies
implicating disruption of synaptic processes in
schizophrenia.45 By identifying an unprecedentedly
large number of de novo CNVs in schizophrenia and
demonstrating that these are likely to be highly
enriched for pathogenic events, we have added
substantially to the evidence implicating synaptic
processes in schizophrenia. As well as implicating a
set of functionally related synaptic proteins (EHMT1,
DLG2, DLG1 and DLGAP1) we have identified a
sufficient number of schizophrenia-enriched loci to
identify potential points on convergence on specific
synaptic complexes. Using gene sets that have been
systematically annotated from individual, high-
quality proteomic data sets and multiple analytic
approaches carefully controlled for biases, we not
only provide strong evidence for the importance of
synaptic proteins, but also provide novel convergent
support for the involvement of NMDAR, and to a
lesser extent ARC protein, complexes in the aetiology
and pathogenesis of the disorder, both of which
are involved in NMDA signal transduction. NMDA
receptor signalling regulates induction of multiple
forms of synaptic plasticity,46 with local synthesis of
ARC central to synaptic remodelling and the long-
term maintenance of synaptic changes.47 Our finding
that 12 out of the 34 case de novos impact on ARC
and/or NMDAR complexes, supported by robust
statistical analyses, suggest that disruption of NMDA
signalling plays a key role in at least some cases of
schizophrenia. As noted above, our findings do not
exclude a role for mutations in other post- or pre-
synaptic complexes, and given the close functional
relationship between different synaptic components,
we might expect pathology at a number of different
points to play a role. Indeed, the robust association
between NRXN1 deletions and schizophrenia48 points
to presynaptic disruption in some cases, a hypothesis
further supported by enrichment for case de novos in
the GO category ‘synaptic vesicle membrane’ after
adjustment for ARC and NMDAR. Our findings
delineate a circumscribed set of largely postsynaptic
proteins and functions that warrant further functional
analysis in model systems.
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